Open Access. Powered by Scholars. Published by Universities.®

Engineering Commons

Open Access. Powered by Scholars. Published by Universities.®

Articles 1 - 3 of 3

Full-Text Articles in Engineering

Surface-Controlled Dissolution Rates: A Case Study Of Nanoceria In Carboxylic Acid Solutions, Eric A. Grulke, Matthew J. Beck, Robert A. Yokel, Jason M. Unrine, Uschi M. Graham, Matthew L. Hancock Apr 2019

Surface-Controlled Dissolution Rates: A Case Study Of Nanoceria In Carboxylic Acid Solutions, Eric A. Grulke, Matthew J. Beck, Robert A. Yokel, Jason M. Unrine, Uschi M. Graham, Matthew L. Hancock

Chemical and Materials Engineering Faculty Publications

Nanoparticle dissolution in local milieu can affect their ecotoxicity and therapeutic applications. For example, carboxylic acid release from plant roots can solubilize nanoceria in the rhizosphere, affecting cerium uptake in plants. Nanoparticle dispersions were dialyzed against ten carboxylic acid solutions for up to 30 weeks; the membrane passed cerium-ligand complexes but not nanoceria. Dispersion and solution samples were analyzed for cerium by inductively coupled plasma mass spectrometry (ICP-MS). Particle size and shape distributions were measured by transmission electron microscopy (TEM). Nanoceria dissolved in all carboxylic acid solutions, leading to cascades of progressively smaller nanoparticles and producing soluble products. The dissolution ...


Amphiphilic Polyanhydride-Based Recombinant Muc4Β-Nanovaccine Activates Dendritic Cells, Kasturi Banerjee, Shailendra K. Gautam, Prakash Kshirsagar, Kathleen A. Ross, Gaelle Spagnol, Paul Sorgen, Michael J. Wannemeuhler, Balaji Narasimhan, Joyce C. Solheim, Sushil Kumar, Surinder K. Batra, Maneesh Jain Mar 2019

Amphiphilic Polyanhydride-Based Recombinant Muc4Β-Nanovaccine Activates Dendritic Cells, Kasturi Banerjee, Shailendra K. Gautam, Prakash Kshirsagar, Kathleen A. Ross, Gaelle Spagnol, Paul Sorgen, Michael J. Wannemeuhler, Balaji Narasimhan, Joyce C. Solheim, Sushil Kumar, Surinder K. Batra, Maneesh Jain

Chemical and Biological Engineering Publications

Mucin 4 (MUC4) is a high molecular weight glycoprotein that is differentially overexpressed in pancreatic cancer (PC), functionally contributes to disease progression, and correlates with poor survival. Further, due to its aberrant glycosylation and extensive splicing, MUC4 is a potential target for cancer immunotherapy. Our previous studies have demonstrated the utility of amphiphilic polyanhydride nanoparticles as a useful platform for the development of protein-based prophylactic and therapeutic vaccines. In the present study, we encapsulated purified recombinant human MUC4-beta (MUC4β) protein in polyanhydride (20:80 CPTEG:CPH) nanoparticles (MUC4β-nanovaccine) and evaluated its ability to activate dendritic cells and induce adaptive immunity ...


Interleukin-1 Alpha Increases Anti-Tumor Efficacy Of Cetuximab In Head And Neck Squamous Cell Carcinoma, Madelyn Espinosa-Cotton, Samuel N. Rodman Iii, Kathleen A. Ross, Isaac J. Jensen, Kenley Sangodeyi-Miller, Ayana J. Mclaren, Rachel A. Dahl, Katherine N. Gibson-Corley, Adam T. Koch, Yang-Xin Fu, Vladimir P. Badovinac, Douglas Laux, Balaji Narasimhan, Andrean L. Simons Jan 2019

Interleukin-1 Alpha Increases Anti-Tumor Efficacy Of Cetuximab In Head And Neck Squamous Cell Carcinoma, Madelyn Espinosa-Cotton, Samuel N. Rodman Iii, Kathleen A. Ross, Isaac J. Jensen, Kenley Sangodeyi-Miller, Ayana J. Mclaren, Rachel A. Dahl, Katherine N. Gibson-Corley, Adam T. Koch, Yang-Xin Fu, Vladimir P. Badovinac, Douglas Laux, Balaji Narasimhan, Andrean L. Simons

Chemical and Biological Engineering Publications

Background: Despite the high prevalence of epidermal growth factor receptor (EGFR) overexpression in head and neck squamous cell carcinomas (HNSCCs), incorporation of the EGFR inhibitor cetuximab into the clinical management of HNSCC has not led to significant changes in long-term survival outcomes. Therefore, the identification of novel therapeutic approaches to enhance the clinical efficacy of cetuximab could lead to improved long-term survival for HNSCC patients. Our previous work suggests that EGFR inhibition activates the interleukin-1 (IL-1) pathway via tumor release of IL-1 alpha (IL-1α), although the clinical implications of activating this pathway are unclear in the context of cetuximab therapy ...